Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes

ACS Chemical Biology

Volumn 9, Issue 8, 2014, Pages 1869-1876

  Li, Hao ^a   Van Der Linden, Wouter A ^a   Verdoes, Martijn ^a   Florea, Bogdan I ^b   McAllister, Fiona E ^a   Govindaswamy, Kavitha ^c   Elias, Joshua E ^a   Bhanot, Purnima ^c   Overkleeft, Herman S ^b   Bogyo, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; LU 102; PR 709A; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG; MOLECULAR PROBE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOREACTOR DESIGN; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBUNIT; FEMALE; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMODIUM; PLASMODIUM CHABAUDI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOLECULAR PROBE;

CATALYTIC DOMAIN; MOLECULAR PROBES; PLASMODIUM; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84906264786     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5001263     Document Type: Article

References (34)

1. World Health Organization. World Malaria Report 2011; World Health Organization: Geneva; 2011.
2. Liu, L., Johnson, H. L., Cousens, S., Perin, J., Scott, S., Lawn, J. E., Rudan, I., Campbell, H., Cibulskis, R., Li, M., Mathers, C., and Black, R. E. (2012) Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000 Lancet 379, 2151-2161
3. Guiguemde, W. A., Shelat, A. A., Garcia-Bustos, J. F., Diagana, T. T., Gamo, F.-J., and Guy, R. K. (2012) Global phenotypic screening for antimalarials Chem. Biol. 19, 116-129
4. Aminake, M. N., Arndt, H.-D., and Pradel, G. (2012) The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention? Int. J. Parasitol.: Drugs and Drug Resistance 2, 1-10
5. Voges, D., Zwickl, P., and Baumeister, W. (1999) The 26S proteasome: A molecular machine designed for controlled proteolysis Annu. Rev. Biochem. 68, 1015-1068
6. Groll, M. (1999) The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study Proc. Natl. Acad. Sci. U. S. A. 96, 10976-10983
7. Bedford, L., Paine, S., Sheppard, P. W., Mayer, R. J., and Roelofs, J. (2010) Assembly, structure, and function of the 26S proteasome Trends Cell Biol. 20, 391-401
8. Chen, P. and Hochstrasser, M. (1996) Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly Cell 86, 961-972
9. Heinemeyer, W., Fischer, M., Krimmer, T., Stachon, U., and Wolf, D. H. (1997) The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing J. Biol. Chem. 272, 25200-25209
10. Arendt, C. S. and Hochstrasser, M. (1997) Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation Proc. Natl. Acad. Sci. U.S.A. 94, 7156-7161
11. Britton, M., Lucas, M. M., Downey, S. L., Screen, M., Pletnev, A. A., Verdoes, M., Tokhunts, R. A., Amir, O., Goddard, A. L., Pelphrey, P. M., Wright, D. L., Overkleeft, H. S., and Kisselev, A. F. (2009) Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites Chem. Biol. 16, 1278-1289
12. Mirabella, A. C., Pletnev, A. A., Downey, S. L., Florea, B. I., Shabaneh, T. B., Britton, M., Verdoes, M., Filippov, D. V., Overkleeft, H. S., and Kisselev, A. F. (2011) Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib Chem. Biol. 18, 608-618
13. Kisselev, A. F. (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate J. Biol. Chem. 281, 8582-8590
14. Meiners, S., Heyken, D., Weller, A., Ludwig, A., Stangl, K., Kloetzel, P.-M., and Krüger, E. (2003) Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes J. Biol. Chem. 278, 21517-21525
15. Parlati, F., Lee, S. J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J. B., Micklem, D. R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K. D., and Bennett, M. K. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 114, 3439-3447
16. Li, H., Ponder, E. L., Verdoes, M., Asbjornsdottir, K. H., Deu, E., Edgington, L. E., Lee, J. T., Kirk, C. J., Demo, S. D., Williamson, K. C., and Bogyo, M. (2012) Validation of the proteasome as a therapeutic target in plasmodium using an epoxyketone inhibitor with parasite-specific toxicity Chem. Biol. 19, 1535-1545
17. Tschan, S., Mordmüller, B., and Kun, J. F. J. (2011) Threonine peptidases as drug targets against malaria Expert Opin. Ther. Targets 15, 365-378
18. Verdoes, M., Florea, B. I., Menendez-Benito, V., Maynard, C. J., Witte, M. D., van der Linden, W. A., van den Nieuwendijk, A. M. C. H., Hofmann, T., Berkers, C. R., and van Leeuwen, F. W. B. (2006) A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo Chem. Biol. 13, 1217-1226
19. Elofsson, M., Splittgerber, U., Myung, J., Mohan, R., and Crews, C. M. (1999) Towards subunit-specific proteasome inhibitors: Synthesis and evaluation of peptide α-, β-epoxyketones Chem. Biol. 6, 811-822
20. Kisselev, A. F., van der Linden, W. A., and Overkleeft, H. S. (2012) Proteasome inhibitors: An expanding army attacking a unique target Chem. Biol. 19, 99-115
21. Geurink, P. P., van der Linden, W. A., Mirabella, A. C., Gallastegui, N., de Bruin, G., Blom, A. E. M., Voges, M. J., Mock, E. D., Florea, B. I., van der Marel, G. A., Driessen, C., van der Stelt, M., Groll, M., Overkleeft, H. S., and Kisselev, A. F. (2013) Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites J. Med. Chem. 56, 1262-1275
22. Screen, M., Britton, M., Downey, S. L., Verdoes, M., Voges, M. J., Blom, A. E. M., Geurink, P. P., Risseeuw, M. D. P., Florea, B. I., van der Linden, W. A., Pletnev, A. A., Overkleeft, H. S., and Kisselev, A. F. (2010) Nature of pharmacophore influences active site specificity of proteasome inhibitors J. Biol. Chem. 285, 40125-40134
23. van der Linden, W. A., Willems, L. I., Shabaneh, T. B., Li, N., Ruben, M., Florea, B. I., van der Marel, G. A., Kaiser, M., Kisselev, A. F., and Overkleeft, H. S. (2012) Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones Org. Biomol. Chem. 10, 181-194
24. Arastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., and Kirk, C. J. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events Clin. Cancer Res. 17, 2734-2743
25. Huber, E. M. and Groll, M. (2012) Inhibitors for the immuno- and constitutive proteasome: Current and future trends in drug development Angew. Chem., Int. Ed. Engl. 51, 8708-8720
26. Ginsburg, H. and Stein, W. D. (2005) How many functional transport pathways does Plasmodium falciparum induce in the membrane of its host erythrocyte? Trends Parasitol. 21, 118-121
27. Reynolds, J. M., Bissati, E. K., Brandenburg, J., Günzl, A., and Mamoun, C. B. (2007) Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B BMC Clin. Pharmacol. 7, 13
28. Prudhomme, J., McDaniel, E., Ponts, N., Bertani, S., Fenical, W., Jensen, P., and Le Roch, K. (2008) Marine actinomycetes: A new source of compounds against the human malaria parasite PLoS One 3, e2335
29. Elfawal, M. A., Towler, M. J., Reich, N. G., Golenbock, D., Weathers, P. J., and Rich, S. M. (2012) Dried whole plant Artemisia annua as an antimalarial therapy PLoS One 7, e52746
30. Stephens, R., Culleton, R. L., and Lamb, T. J. (2012) The contribution of Plasmodium chabaudi to our understanding of malaria Trends Parasitol. 28, 74-83
31. Gantt, S. M., Myung, J. M., Briones, M. R., Li, W. D., Corey, E. J., Omura, S., Nussenzweig, V., and Sinnis, P. (1998) Proteasome inhibitors block development of Plasmodium spp Antimicrob. Agents Chemother. 42, 2731-2738
32. Bozdech, Z., Llinás, M., Pulliam, B. L., Wong, E. D., Zhu, J., and DeRisi, J. L. (2003) The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum PLoS Biol. 1, e5
33. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H. M., and Voll, R. E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Res. 67, 1783-1792
34. Legesse-Miller, A., Raitman, I., Haley, E. M., Liao, A., Sun, L. L., Wang, D. J., Krishnan, N., Lemons, J. M. S., Suh, E. J., Johnson, E. L., Lund, B. A., and Coller, H. A. (2012) Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity Mol. Biol. Cell 23, 3566-3581